Ichnos Glenmark Innovation Receives U.S. FDA Fast Track Designation for ISB 2001 for Relapsed / Refractory Multiple Myeloma

Ichnos Glenmark Innovation United States of America New York Austria France Germany Switzerland United Kingdom

View original content:https://www.prnewswire.co.uk/news-releases/ichnos-glenmark-innovation-igi-receives-us-fda-fast-track-designation-for-isb-2001-for-relapsedrefractory-multiple-myeloma-302445928.html